Clinical Dilemmas in Liver Cancer follows the successful format of the other books in the Clinical Dilemmas series, with each chapter focused on a specific dilemma, or issue facing doctors in their day-to-day job, and providing them with practical clinical information and help to better assessment and treat their patients - in this case patients suffering from liver cancer, the third commonest cancer in terms of mortality worldwide. Chapters feature up-to-date information on the basic mechanisms, epidemiological risk factors, screening and surveillance strategies, diagnosis and treatment. It is an extremely practical and clinically-orientated book, and as most patients around the world present with advanced disease, a main focus is on the most recent advances allowing early diagnosis and use of locoregional and systemic therapy, surgery, transplantation and combination therapies. Each chapter is authored by an international expert in the relevant area.
List of Contributors, vii Preface, x Part 1: Learning from a Worldwide Perspective 1 Are patterns and prevalence changing?, 3 Hashem B. El-Serag 2 Why is the tumour different in Africa?, 11 Nimzing G. Ladep 3 Control by vaccination: Asian and Taiwan experience, 18 Jia-Horng Kao 4 The view from the United Kingdom, 24 Shahid A. Khan, Mireille B. Toledano, Abigail Zabron, Mehtan Ahmed, and Simon D. Taylor-Robinson 5 The view from the United States, 29 Hitoshi Maruyama and Arun J. Sanyal 6 New challenges of the NAFLD and HIV epidemics, 35 Quentin M. Anstee and Janice Main Part 2: Influence of Tumour Characteristics 7 Controversies in pathology, 45 Tania Roskams 8 Not to forget the unusual tumour, 53 Bernard C. Portmann 9 What can be learned from molecular diagnostic techniques and genetic signatures?, 60 Tariq Moatter and Saeed Hamid Part 3: Complexities of Patient Assessment and Scoring Systems 10 Looking after the liver as well as the tumour, 67 Roger Williams 11 Comparative performances of staging systems for hepatocellular cancer: early HCC considerations, 75 Peter D. Peng and Timothy M. Pawlik 12 Rival scoring systems: do they offer more?, 81 Angelo Sangiovanni and Massimo Colombo 13 Is it possible to detect early lesions effectively?, 91 Ryota Masuzaki and Masao Omata 14 What is the value of country-based surveillance programmes?, 97 Peter Ott Part 4: Choice of Radiological Diagnostic Technique 15 Computed tomography or magnetic resonance imaging for the diagnosis of hepatocellular carcinoma, 107 Wladyslaw Gedroyc 16 Is Microbubble ultrasound useful?, 114 Adrian Lim 17 Value of PET scanning, 118 Tara D. Barwick, Imene Zerizer, and Adil Al-Nahhas Part 5: Can Treatment be Tailored to the Patient? 18 Who could benefit from chemoembolisation?, 127 Gisele N'Kontchou, Olivier Seror, and Michel Beaugrand 19 Are drug-eluting beads worth using?, 136 Christopher N. Hacking and Pradesh Kumar 20 What is the future of image-guided radiofrequency ablation for hepatocellular carcinoma?, 142 Riccardo Lencioni 21 Alternative ablation techniques for hepatocellular carcinoma, 149 John Karani 22 Justification for sorafenib and chemotherapy, 154 Philip J. Johnson 23 When to consider surgery?, 160 Emmanuel Melloul, Mickael Lesurtel, and Pierre-Alain Clavien 24 Transplant considerations, 168 Myron Schwartz Part 6: What Does the Future Hold? 25 Dipstick markers for diagnosis: feasible or not?, 179 Mohamed I.F. Shariff and Simon D. Taylor-Robinson 26 Targeted gene therapy for hepatocellular carcinoma: a reality?, 184 Christopher Binny, Marco Della Peruta, and Amit C. Nathwani 27 Is immune modulation a possibility?, 191 Tim F. Greten and Firouzeh Korangy 28 Systemic therapy for hepatocellular carcinoma: future directions, 199 Daniel H. Palmer, Matthew E. Cramp Index, 212 Colour plate section can be found facing page 86